Theodore Alan Huizenga

CIK 1603347 · SVP, Chief Accounting Officer · last filed 2026-09-15

Theodore Alan Huizenga is a SVP, Chief Accounting Officer who has filed 71 SEC Form 4 insider transactions across 1 company since 2015. The most recent filing, for RARE, was dated Sep 15, 2026. Across all open-market trades the lifetime net is −$3.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.0M across reported positions. 70 SEC filings were submitted jointly with Ultragenyx Pharmaceutical Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$1.01M

Companies

Total Filings

Lifetime Open-Market Net

-$3.27M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

Filer Profile

Reported Address

C/O ULTRAGENYX PHARMACEUTICAL INC.
60 LEVERONI COURT
NOVATO, CA 94949

Related Filers

Ultragenyx Pharmaceutical Inc. — 70 joint filings, latest 2026-04-24

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
RARE	SVP, Chief Accounting Officer	67,863	$14.88	$1.01M	-$3.27M	69	2026-09-15

Recent Filings

71 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2026-09-15	RARE	Notice (144)	−1,283	-$17.5K	EDGAR
2026-09-15	RARE	Sell (S)	−1,283	-$17.4K	EDGAR
2026-09-08	RARE	Sell (S)	−161	-$2.3K	EDGAR
2026-04-24	RARE	Grant (A)	+20,241	$0	EDGAR
2026-03-03	RARE	Mixed	−1,780	-$40.7K	EDGAR
2025-12-30	RARE	Sell (S)	−85	-$2.9K	EDGAR
2025-09-19	RARE	Sell (S)	−64	-$1.9K	EDGAR
2025-09-08	RARE	Sell (S)	−84	-$2.6K	EDGAR
2025-03-04	RARE	Mixed	+8,284	-$46.8K	EDGAR
2024-12-11	RARE	Gift (G)	−648	$0	EDGAR

Showing 1–10 of 71

Page 1 of 8 Next

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.